{"filings":[{"id":759721,"accession_number":"0001104659-26-068591","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-06-01T12:00:26+00:00","items":["8.01"],"status":"ready","headline":"FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["VY1706 targets intra- and extracellular tau; IND cleared by FDA on June 1, 2026.","Phase 1 open-label, dose-escalation trial expected to begin dosing in H2 2026.","Trial to enroll up to 18 early AD patients across 3 cohorts; highest dose 5 x 10^13 vg/kg.","Primary endpoint: safety/tolerability; secondary endpoints: CSF tau biomarkers and tau PET imaging.","Company plans to initiate multi-site study; VY1706 administered as one-time IV dose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94311,"accession_number":"0001104659-26-057115","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q1 net loss $27.9M, cash $172M into 2028; VY1706 tau gene therapy on track for H2 dosing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.9M (Q1 2026) vs $31.0M (Q1 2025); revenue $2.6M down from $6.5M due to lower collaboration revenue.","Cash, equivalents and marketable securities $171.7M; runway expected into 2028.","VY1706 tau silencing gene therapy: IND-enabling GLP tox completed; FDA IND on track for Q2, first-in-human dosing H2 2026.","VY7523 anti-tau antibody: tau PET imaging efficacy data from MAD trial expected H2 2026.","Neurocrine's NBIB-'223 for Friedreich's ataxia: GLP tox completed, FDA orphan drug designation; clinical trial H2 2026 pending IND."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":2593000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94310,"accession_number":"0001104659-26-045997","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Voyager Therapeutics CFO Nathan Jorgensen resigns; Robin Swartz named PFO, Amy Quinlan PAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Nathan Jorgensen, Ph.D. resigns effective May 8, 2026, to pursue new opportunity; no disagreement with company.","Board appoints Robin Swartz (COO/CBO) as principal financial officer and treasurer effective May 8, 2026.","Board appoints Amy Quinlan (VP Finance) as principal accounting officer effective May 8, 2026.","Swartz previously served as interim PFO and PAO in 2024; Quinlan joined in Jan 2025 from Vor Biopharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106577,"accession_number":"0001104659-26-025201","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q4 2025 net loss $27.4M, cash $201.7M; key pipeline milestones H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $27.4M vs $34.5M in Q4 2024; full year net loss $119.7M vs $65.0M.","Collaboration revenue Q4 $15.3M (up 143% YoY) but full year $40.4M (down 50% YoY).","Cash $201.7M at Dec 31 2025; runway expected into 2028 with up to $2.4B in milestone potential.","VY1706 (tau-silencing) IND planned Q2 2026, first-in-human dosing H2 2026; VY7523 tau PET data H2 2026.","APOE gene therapy program paused; Neurocrine milestone $3M triggered in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106576,"accession_number":"0001104659-26-013897","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Chief Medical Officer Toby Ferguson resigns; CEO Sandrock takes over clinical leadership","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Toby Ferguson, M.D., Ph.D., resigned as CMO effective Feb 20, 2026, to pursue a new opportunity.","Resignation is not due to any disagreement with the company.","CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will assume interim oversight of clinical development programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106575,"accession_number":"0001104659-26-001955","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Voyager Therapeutics outlines pivotal 2026 milestones: tau programs, capsid validation, NeuroShuttle data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Biogen's BIIB080 Phase II data expected mid-2026; Voyager's VY1706 gene therapy first-in-human in H2 2026.","VY7523 anti-tau antibody trial fully enrolled; tau PET imaging data expected H2 2026.","Neurocrine plans to initiate clinical trial with NBIB-‘223 for Friedreich's ataxia in 2026.","ALPL-NeuroShuttle shows similar target engagement to TfR shuttle with more sustained brain exposure; partnering interest strong.","Four wholly owned and partnered IV-delivered neuro gene therapy programs advanced to preclinical toxicology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122908,"accession_number":"0001104659-25-108841","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q3 net loss widens to $27.9M; cash runway into 2028; NeuroShuttle platform launched","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.9M (vs $9.0M in Q3 2024); collaboration revenue fell to $13.4M from $24.6M.","Cash, equivalents, marketable securities $229M; runway extended into 2028.","New collaboration with Transition Bio for TDP-43 small molecules (ALS/FTD); upfront single-digit million, milestones up to $500M.","Introduced ALPL-VYGR-NeuroShuttle nonviral platform; murine data shows >3 weeks brain expression.","Novartis discontinues two discovery programs (rights return); Neurocrine milestone $3M expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":25038000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139606,"accession_number":"0001104659-25-085977","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Voyager Therapeutics presents at Citi Biopharma Conference; no specific updates disclosed in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company presented at Citi's 2025 Biopharma Back to School Conference on September 2, 2025.","Presentation titled 'Leveraging Genetics to Treat Neurological Diseases' focuses on genetic approaches.","No financial results, pipeline milestones, or guidance changes are identifiable from the provided excerpt.","The filing does not contain material new information beyond the fact of the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139605,"accession_number":"0001558370-25-010507","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q2 net loss widens to $33.4M; cash runway extended into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.4M in Q2 2025 vs $10.1M in Q2 2024; collaboration revenue fell to $5.2M from $29.6M.","Cash and marketable securities $262M; runway extended into 2028, enabling multiple clinical data readouts.","Added wholly-owned APOE program to Alzheimer's pipeline, fourth asset in franchise; tau PET data for VY7523 expected H2 2026.","Neurocrine-partnered FA and GBA1 gene therapy programs expected to enter clinical trials in 2026 after IND submissions in 2025.","Potential for $2.6B in development milestone payments from 11 partnered programs, including up to $35M from GBA and FA programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":11673000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157187,"accession_number":"0001104659-25-056835","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Voyager stockholders approve 2025 stock plans, elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approved 2025 Stock Incentive Plan: 28.6M for, 11.3M against, 8.5M broker non-votes.","Approved Amended and Restated 2015 ESPP: 36.5M for, 3.3M against, 8.5M broker non-votes.","Elected Class I directors Colón, Mackey, Pierce, Scangos; Scangos had 6.7M votes withheld.","Ratified Ernst & Young as FY2025 auditor: 48.1M for, 0.25M against.","Say-on-pay approved: 37.8M for, 2.0M against, 0.1M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157186,"accession_number":"0001558370-25-006482","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q1 2025 net loss $31.0M, revenue down 67% YoY; cash $295M into mid-2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $31.0M vs $11.3M YoY; collaboration revenue $6.5M vs $19.5M YoY (−67%).","Cash, cash equivalents & marketable securities $295M; expects runway into mid-2027.","R&D expenses $31.5M (+16% YoY); G&A $9.6M (+12% YoY).","VY1706 tau silencing gene therapy achieved up to 73% tau mRNA knockdown in NHPs; IND/CTA filings expected 2026.","Neurocrine-partnered FA and GBA1 IND submissions on track for 2025; up to $35M milestone potential 2025-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":6473000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175534,"accession_number":"0001558370-25-002702","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Therapeutics Q4 2024 net loss $34.5M; tau gene therapy VY1706 IND filing planned for 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.5M in Q4 2024 vs net income $56.4M in Q4 2023; full year net loss $65.0M vs income $132.3M.","Collaboration revenue $6.3M in Q4 2024 vs $90.1M in Q4 2023; $80.0M full year vs $250.0M in 2023.","Cash and marketable securities $332.4M as of Dec 31, 2024; runway extended into mid-2027 excluding milestones.","Tau silencing gene therapy VY1706 reduced tau mRNA 50-73% in NHP study; IND filing anticipated in 2026.","Anti-tau antibody VY7523 MAD study initiated; initial tau PET data in Alzheimer's patients expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175533,"accession_number":"0001104659-25-011155","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Voyager delays SOD1 ALS IND filing; switches payload after NHP data; cash runway to mid-2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VY9323 IND/CTA filing no longer expected mid-2025 due to need for alternate payload after 3-month NHP data.","Capsid unchanged; decision based on achieving desired product profile for SOD1 ALS gene therapy.","Other programs unaffected: Neurocrine GBA1 and Friedreich’s ataxia IND filings still on track for 2025.","Tau silencing program VY1706 IND expected in 2026; preclinical activity levels achieved.","Cash and equivalents plus collaboration reimbursements fund operations into mid-2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192488,"accession_number":"0001558370-24-015299","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q3 net loss narrows to $9.0M; new Novartis capsid license; VY7523 SAD data H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 collaboration revenue $24.6M (up from $4.6M YoY); net loss $9.0M vs $25.9M.","Licensed TRACER capsid to Novartis for undisclosed rare neurologic target; $15M upfront, up to $305M milestones.","Neurocrine partnership selected 3rd development candidate, triggering $3M milestone.","VY7523 anti-tau antibody SAD trial enrollment complete; top-line safety/PK data expected H1 2025.","Cash $345.4M at Sep 30; plus $18M received in Oct; runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":73723000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208959,"accession_number":"0001104659-24-097152","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Voyager grants Novartis license to capsid for gene therapy; $15M upfront, up to $305M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Novartis receives exclusive license to a capsid from Voyager's TRACER platform for a single gene target.","One-time $15M fee paid upfront; Voyager eligible for $130M in development/regulatory/commercial milestones.","Additional sales milestones up to $175M per product plus tiered mid- to high-single-digit royalties.","Novartis' prior option rights for other targets expired as of September 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208958,"accession_number":"0001558370-24-011071","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q2 net loss narrows to $10.1M; cash $371M; anti-tau trial underway, data H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 collaboration revenue $29.6M (vs $4.9M YoY); net loss $10.1M vs $22.2M loss a year earlier.","Cash, equivalents and marketable securities at $371M as of June 30; runway into 2027.","First participants dosed in Phase 1a SAD of anti-tau antibody VY7523; top-line safety/PK data expected H1 2025.","Three gene therapy INDs on track for 2025: SOD1 ALS (VY9323), GBA1, and Friedreich's ataxia.","Appointed Nathan Jorgensen as CFO; received $3M milestone from Neurocrine for GBA1 candidate selection."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":49094000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226784,"accession_number":"0001104659-24-071048","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Voyager Therapeutics appoints Nathan Jorgensen as CFO effective July 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jorgensen, 47, previously CFO of Vor Biopharma; will report to CEO Alfred Sandrock.","Annual base salary of $480,000; target annual bonus of 40% of base salary.","Inducement equity grants: option to purchase 200,000 shares (4-year vest) and RSU for 80,000 shares (3-year vest).","Severance: 12 months base salary plus pro-rata bonus and COBRA on termination without cause or for good reason within 12 months of a sale event.","Employment at-will; standard non-compete and non-solicitation provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226783,"accession_number":"0001104659-24-069063","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Voyager stockholders elect three Class III directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Michael Higgins, Jude Onyia, and Nancy Vitale elected Class III directors until 2027.","Non-binding advisory vote on executive compensation passed with 35.9M for vs 1.7M against.","Ratification of Ernst & Young as independent auditor for FY2024 with 46.3M for, 72K against.","Broker non-votes of 8.6M on director elections and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226782,"accession_number":"0001104659-24-062257","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Voyager Therapeutics doses first participants in Phase 1a trial of anti-tau antibody VY-TAU01 for Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First participants dosed in Phase 1a SAD trial of VY-TAU01, an anti-tau antibody for Alzheimer's disease.","Trial is randomized, double-blind, placebo-controlled, evaluating safety and PK in healthy adult volunteers.","Study conducted at a single U.S. site; expected to enroll approximately 48 patients across multiple cohorts.","VY-TAU01 designed to inhibit spread of pathological tau in Alzheimer's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226781,"accession_number":"0001558370-24-007951","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Q1 net loss $11.3M; IND cleared for VY-TAU01; cash $400M to 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.3M vs net income of $124.0M in Q1 2023; collaboration revenue $19.5M down from $150.5M.","Cash, equivalents and marketable securities of $400.5M as of March 31, 2024; runway into 2027.","IND clearance from FDA for anti-tau antibody VY-TAU01 for Alzheimer's disease; Phase 1a dosing imminent.","Development candidates selected in GBA1 and Friedreich's Ataxia gene therapy programs with Neurocrine; $8M total milestones triggered.","Appointed Toby Ferguson, M.D., Ph.D., as Chief Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":19516000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226780,"accession_number":"0001104659-24-042502","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Voyager Therapeutics CFO Peter Pfreundschuh to resign; Robin Swartz appointed as principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Peter Pfreundschuh resigns effective April 12, 2024; remains as Senior Financial Advisor until May 5, 2024.","Robin Swartz, current COO, appointed principal financial and accounting officer effective April 12.","Pfreundschuh receives salary continuation for 12 months, prorated 2024 bonus, and health insurance.","Unvested equity awards continue to vest during consulting period up to ~July 2024.","Separation Agreement includes release of claims and non-disparagement obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245744,"accession_number":"0001104659-24-033726","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Voyager Therapeutics names Toby Ferguson as Chief Medical Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment starts March 25, 2024; base salary $485,000, target bonus 40%.","Granted inducement option for 210k shares and RSU for 105k shares, both time-vesting.","Dr. Ferguson previously VP, Head of Neuromuscular Development at Biogen (2013-2024).","Severance provides 12 months base salary and pro-rata bonus if terminated without cause or for good reason within 12 months post sale event.","At-will employment; standard non-compete and confidentiality obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245743,"accession_number":"0001558370-24-001987","cik":1640266,"company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Voyager Therapeutics reports Q4 net income $56.4M, pro-forma cash $431M, pipeline milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 collaboration revenue $90.1M (vs -$1.6M YoY), net income $56.4M (vs loss $23.6M).","FY 2023 collaboration revenue $250.0M (vs $40.9M), net income $132.3M (vs loss $46.4M).","Pro-forma cash $431M after Novartis $100M and Jan 2024 $100M public offering; runway into 2027.","Selected development candidates: SOD1 ALS gene therapy (IND mid-2025) and Friedreich's ataxia (triggered $5M milestone, clinic 2025).","Novartis collaboration: $80M upfront + $20M equity, up to $1.2B milestones; VY-TAU01 IND expected H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":2.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":250008000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":210270000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}